scholarly journals Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma – a pilot study

2020 ◽  
Vol 37 (4) ◽  
pp. 548-558
Author(s):  
András Bánvölgyi ◽  
Kende Lőrincz ◽  
Norbert Kiss ◽  
Pinar Avci ◽  
Luca Fésűs ◽  
...  
Keyword(s):  
Ascorbic Acid ◽  
Pilot Study ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Locally Advanced ◽  
High Dose ◽  
Acid Therapy ◽  
Intravenous Ascorbic Acid ◽  
Advanced Basal Cell Carcinoma

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients

2019 ◽  
Vol 37 (34) ◽  
pp. 3275-3282 ◽  
Author(s):  
Florian Herms ◽  
Jerome Lambert ◽  
Jean-Jacques Grob ◽  
Luc Haudebourg ◽  
Martine Bagot ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Objective Response Rate ◽  
Response Rate ◽  
Objective Response ◽  
Locally Advanced ◽  
Advanced Basal Cell Carcinoma

PURPOSE Vismodegib is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (laBCC), with an objective response rate of 65%, including a 32% complete response (CR). However, adverse effects often lead to drug discontinuation. The objective of our study was to evaluate long-term responses, predictive factors, and management of relapse after vismodegib discontinuation. METHODS An observational retrospective study was conducted in nine French oncodermatology units. We included patients with laBCC with CR on vismodegib who discontinued treatment between March 2012 and January 2016; we reviewed charts up to June 2016. The primary objective was to evaluate median relapse-free survival (RFS). Secondary objectives were risk factors associated with RFS, relapse, and death and treatment modalities after relapse and their efficacy. RESULTS One hundred sixteen patients with laBCC were included. The median RFS was 18.4 months (95% CI, 13.5 to 24.8 months). The RFS rate at 36 months was 35.4% (95% CI, 22.5% to 47.9%) for the total population and 40.0% (95% CI, 25.7% to 53.7%) for patients without Gorlin syndrome. LaBCC to the limbs and trunk was the only variable independently associated with a higher risk of relapse (hazard ratio, 2.77; 95% CI, 1.23 to 6.22; P = .019). Twenty-seven patients (50%) who experienced relapse during follow-up were retreated with vismodegib, with an objective response in 23 (objective response rate, 85%; CR rate, 37%; partial response rate, 48%) and eligibility for surgery in 24 (42%). CONCLUSION Long-term response after vismodegib discontinuation is frequent. Most patients who experience a relapse still respond to vismodegib rechallenge.

Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: A retrospective multicentric French study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 9535-9535 ◽  
Author(s):  
Florian Herms ◽  
Luc Haudebourg ◽  
Martine Bagot ◽  
Caroline Dutriaux ◽  
Jean Jacques Grob ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Predictive Factors ◽  
Basal Cell ◽  
Locally Advanced ◽  
Risk Of Relapse ◽  
Advanced Basal Cell Carcinoma

9535 Background: Vismodegib is a Hedgehog Pathway inhibitor (HPI) indicated for treatment of inoperable locally advanced basal-cell carcinoma (laBCC). Previous studies showed an objective response (OR) rate of 67%, including 34% of complete response (CR). Discontinuation of vismodegib is very frequent, mostly due to intolerable side-effects. Long-term response and predictive factors of relapse after suspension of vismodegib have not yet been evaluated, but should play a crucial role in the management of laBCC patients. Methods: We conducted an observational retrospective study in 9 onco-dermatological French units. Medical charts of laBCC patients treated with vismodegib from March 2012 until June 2016 were reviewed and patients with CR who stopped treatment were selected. Relapse was diagnosed clinically and/or histologically. A survival analysis was conducted, and predictive factors, characterization and management of relapse were studied. Results: 119 laBCC patients achieved CR and stopped treatment. 21 were lost to follow-up and 6 died before relapse. Event-free survival median was 18.4 months (12.1 – 24.1) and cumulative incidence of relapse at 36 months was 59.04% (48.05 - 70.04), implying that more than 40% of patients do not relapse. Multiple BCC and BCC not localized on the head and neck were associated with a higher risk of relapse, independently of the existence of Gorlin syndrome (HR = 3.3 (IC95 = 1.6 - 6.7) and 2.01 (IC95 = 1.05 - 3.87) respectively). Total duration of treatment was not associated with relapse. 50% (n = 27) of patients who relapsed during follow-up were retreated with vismodegib, with an OR of 85.2% (n = 23). 42% (n = 24) were eligible to surgery only and other patients received local treatments. Conclusions: Long term responders after vismodegib treatment discontinuation are frequent independently of the time exposure to the drug before and after CR. Most patients who relapse are still responder to vismodegib rechallenge. Patients with multiple or laBCC not localized on the head and neck are more at risk of relapse after discontinuation. This study emphasizes the interest of treatment of laBCC with HPI.

Neoadjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma

2021 ◽  
pp. 100736
Author(s):  
Diya M Sabu ◽  
Jeska Kroes ◽  
Charles Gilham ◽  
Ann Fleming ◽  
Fergal C Kelleher
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Advanced Basal Cell Carcinoma

Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Shane D. B. Smith ◽  
Callisia N. Clarke ◽  
Melanie A. Clark ◽  
Amy K. Harker-Murray ◽  
Olayemi Sokumbi
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Advanced Basal Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document